Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (September 2024)
17 slides from Nyrada's investor presentation, Sep 17, 2024
Slide 1: Nyrada Inc. Investor Presentation
Nyrada Inc. For personal use only Investor Presentation September 2024 Improving Lives, Offering Hope Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. ASX:NYR NYRADA INC (ASX:NYR) 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should Although the Company believes that the expectations reflected in the forward-looking For personal use only not be considered as an offer or invitation to subscribe for, or purchase any s
Slide 3: Mr James Bonnar, Chief Executive Officer
For personal use only Mr James Bonnar Nyrada Chief Executive Officer NYRADA INC (ASX:NYR) 3
Slide 4: Nyrada's Expertise in Drug Development
Nyrada’s Expertise in Drug Development For personal use only › Drug discovery and development company specialising in rational design of novel small molecule therapeutics. › Nyrada’s lead drug candidate NYR-BI03: › demonstrated strong preclinical efficacy protecting the brain from secondary injury.
Slide 5: Nyrada Investment Proposition
Nyrada Investment Proposition For personal use only › Pioneering transient receptor potential canonical (TRPC) channel blocking therapies. › First-in-class neuroprotection therapy with novel mode of action. › Brain injury program targeting significant market and unmet clinical demand. › Collaboratio
Slide 6: Large Market Opportunity – Stroke
Large Market Opportunity – Stroke For personal use only Globally: ~15 million ~5 million people suffer left permanently strokes annually1 disabled1 One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator). Effective treatment will improve patient outcomes
Slide 7: Large Market Opportunity – Traumatic Brain Injury (TBI)
Large Market Opportunity – Traumatic Brain Injury (TBI) For personal use only Globally: ~5.5 million ~55 million people suffer severe living with effects of TBI annually3 medically treated TBI3 No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs
Slide 8: Nyrada Brain Injury Program
Nyrada Brain Injury Program For personal use only NYRADA INC (ASX:NYR) 8
Slide 9: Nyrada's Lead Brain Injury Candidate – NYR-BI03
Nyrada’s Lead Brain Injury Candidate – NYR-BI03 For personal use only First-in-Class with Novel Significant Unmet Clinical Mechanism of Action Need and Market Opportunity › NYR-BI03 is a first-in-class therapy. › Targeting multiple indications. › Novel mechanism of action. › Stroke and TBI are leadi
Slide 10: Statistically Significant Neuroprotection Achieved
Statistically Significant Neuroprotection Achieved Recent preclinical study demonstrated strong efficacy and good tolerability For personal use only 42% 41% Study Design of brain injury in penumbra region mean level of biomarkers for NYR-BI03 • The study involved inducing a focal rescued on average
Slide 11: Brain Injury Trajectory, Patient Outcomes, Treatment Aims
Brain Injury Trajectory, Patient Outcomes, Treatment Aims Serial reconstruction from MRI Primary Secondary Disability For personal use only 30 mins Injury Injury Level IMPROVED BECAME STAYED DIED WORSE THE SAME 72 hours Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyr
Slide 12: TRPC 3/6/7 Ion Channels as a Therapeutic Target
TRPC 3/6/7 Ion Channels as a Therapeutic Target › Glutamate release following brain injury results in calcium entry via TRPC ion channels For personal use only › Excessive calcium build-up leads to neuronal cell death › Blocking TRPC 3/6/7 ion channels is neuroprotective against secondary brain inju
Slide 13: NYR-BI03 Good Laboratory Practice (GLP) Safety Studies
NYR-BI03 Good Laboratory Practice (GLP) Safety Studies For personal use only GLP Study Reported AMES 16 July 2024 hERG 16 July 2024 Rat CNS 06 August 2024 Rat Respiratory 20 August 2024 Dog cardiovascular safety 09 September 2024 14-day dog toxicology 14-day rat toxicology In vitro micronucleus In v
Slide 14: Indicative Phase I Study Design
Brain Injury Program - Indicative Phase I Study Design OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 For personal use only DESIGN • Randomised, double-blind placebo – PARTICIPANTS controlled, dose escalation design • Male and female healthy volunteers • 5 cohorts; 8
Slide 15: Near Term Catalysts and Newsflow
Near Term Catalysts and Newsflow For personal use only › Early October 2024 – 1QFY2025 Cashflow and business update. › 2HCY2024 – Good Laboratory Practice (GLP) safety and tolerability study updates. › 4QCY2024 – Human Research Ethics Committee application submission. › 4QCY2024 – First-in-human Pha
Slide 16: References
References 1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular- accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20is%20high%20blood%20pressure For personal use only 2 – Databridge Market Research - https://www.databridgemark
Slide 17: Brain Injury Solution Animation
For personal use only Brain Injury Solution Animation @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 17